Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex Dose Finding for Reversal of Rocuronium-induced Neuromuscular Blockade in Children Under 2 Years
NCT06575036Phase 2Not yet recruiting
- Start
- Sep 2024
- Primary completion
- Apr 2025
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Sugammadex in neuromuscular blockade (NMB). Primary endpoints: 50% Effective Dose at 2 minutes and 95% Effective Dose at 2 minutes. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT06575036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06575036.